The historical rank and industry rank for Corcept Therapeutics's Net Margin % or its related term are showing as below:
CORT'
s Net Margin % Range Over the Past 10 Years
Min: 6.16 Med: 27.6 Max: 81.11
Current: 6.16
CORT's Net Margin % is ranked better than 77.4% of 947
companies
in the Biotechnology industry
Industry Median: -89.56
vs CORT: 6.16
Corcept Therapeutics (NAS:CORT) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Corcept Therapeutics Net Margin % Related Terms
Corcept Therapeutics Net Margin % Historical Data
* Premium members only.
The historical data trend for Corcept Therapeutics's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Corcept Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corcept Therapeutics Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corcept Therapeutics's Net Margin % distribution charts can be found below:
* The bar in red indicates where Corcept Therapeutics's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corcept Therapeutics (CORT) has a Net Margin % of -19.26% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Corcept Therapeutics and its competitors. Over the past decade, Corcept Therapeutics' Net Margin % has ranged from 6.16 to 81.11. According to the industry distribution chart, Corcept Therapeutics ranks #214 out of 947 companies in the Biotechnology industry, placing it in the top 22.6%.
Is Corcept Therapeutics' Net Margin % too high?
Corcept Therapeutics' current Net Margin % is -19.26%. Over the past 10 years, this metric has ranged from a low of 6.16 to a high of 81.11. Based on the distribution chart, Corcept Therapeutics ranks #214 out of 947 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Corcept Therapeutics has a GF Score™ of 82/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Corcept Therapeutics' Net Margin % compare to PCVX and IBRX?
According to the Biotechnology industry distribution chart, Corcept Therapeutics ranks #214 out of 947 companies for Net Margin %. This places Corcept Therapeutics in the top 23% of its industry — outperforming the majority of peers. Historically, Corcept Therapeutics' own Net Margin % has ranged from 6.16 to 81.11 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Corcept Therapeutics and its competitors. Corcept Therapeutics's current Net Margin % is -19.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corcept Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Corcept Therapeutics (CORT) is currently considered Significantly Overvalued. The stock's GF Value™ is $61.59, compared to a current price of $81.56 — trading 32.4% above its estimated fair value. The current Net Margin % is -19.26%. Corcept Therapeutics' overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Corcept Therapeutics (CORT), the current Net Margin % is -19.26% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Corcept Therapeutics (CORT) Overvalued in 2026?
Based on GuruFocus' analysis, Corcept Therapeutics stock appears to be overvalued.
The current stock price of $81.56 is trading 32.4% above its estimated GF Value™ of $61.59.
GuruFocus considers Corcept Therapeutics to be Significantly Overvalued.
Key valuation signals for CORT:
Net Margin %: -19.26%
GF Value™: $61.59 vs. price of $81.56 (32.4% above fair value)
No single metric tells the full story. See the CORT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
82GF Score
Get the complete analysis for CORT
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CORT has been successfully added to your 
